Business
4D Molecular Therapeutics Reports Financial Results for the Second Quarter of 2021 and Provides Operational Highlights
EMERYVILLE, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of
About this update from 4d Molecular Therapeutics, Inc.
[{"type":"text","content":"EMERYVILLE, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced financial results for the second quarter of 2021, and provided operational highlights. “Harnessing the power of directed evolution to develop targeted gene therapies is central to 4DMT, and this past quarter we continued to make substantial progress towards our goal,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT. “Importantly, we initiated the expansion of our cGMP manufacturing facilities to support commercial-scale production of our clinical product candidates. Notably, we believe we are the first AAV gene therapy company to successfully complete cGMP manufacturing of primate-evolved targeted vectors, and we achieved this milestone with three different clinical product candidates. This achievement underscores the promise of our Therapeutic Vector Evolution platform, which empowers us to invent targeted and evolved vectors that package efficiently during our proprietary manufacturing process. In addition, we enhanced our leadership team with the additions of Carolyne Zimmermann as Chief Business Officer and Nadine Greiner, Ph.D., as Chief Human Resources Officer. We remain on track to announce clinical data from each of our three ongoing clinical programs and to initiate clinical development with product candidates in wet AMD and cystic fibrosis by the end of this year.” Recent Operational Highlights Initiated the expansion of current Good Manufacturing Practices (cGMP) compliant manufacturing facilities and analytical laboratories at 4DMT headquarters in Emeryville, CA to support manufacturing and analytical testing of current and future product candidates. The expanded facility will enable commercial-scale manufacturing of our clinical product candidates and expansion of our analytical development capabilities, including laboratories dedicated for developing potency assays.Appointed Carolyne Zimmermann as Chief Business Officer. Ms. Zimmermann brings over 27 years of leadership experience in life sciences corporate and business development, including from her prior roles at Johnson & Johnson Innovation and Novartis Pharmaceuticals.Appointed Nadine Greiner, Ph.D. as Chief Human Resources Of...